Urologicals, urinary antispasmodics. ATC Code:
Pharmacology: Pharmacodynamics: Mechanism of Action:
Mirabegron is a potent and selective β3
-adrenoceptor agonist. Mirabegron showed relaxation of bladder smooth muscle in rat and human isolated tissue, increased cyclic adenosine monophosphate (cAMP) concentrations in rat bladder tissue and showed a bladder relaxant effect in rat urinary bladder function models. Mirabegron increased mean voided volume per micturition and decreased the frequency of non-voiding contractions, without affecting voiding pressure or residual urine in rat models of bladder over activity. In a monkey model, mirabegron showed decreased voiding frequency. These results indicate that mirabegron enhances urine storage function by stimulating β3
‑adrenoceptors in the bladder.
During the urine storage phase, when urine accumulates in the bladder, sympathetic nerve stimulation predominates. Noradrenaline is released from nerve terminals, leading predominantly to β-adrenoceptor activation in the bladder musculature, and hence bladder smooth muscle relaxation. During the urine voiding phase, the bladder is predominantly under parasympathetic nervous system control. Acetylcholine, released from pelvic nerve terminals, stimulates cholinergic M2 and M3 receptors, inducing bladder contraction. The activation of the M2 pathway also inhibits β3
‑adrenoceptor induced increases in cAMP. Therefore β3
-adrenoceptor stimulation should not interfere with the voiding process. This was confirmed in rats with partial urethral obstruction, where mirabegron decreased the frequency of non-voiding contractions without affecting the voided volume per micturition, voiding pressure or residual urine volume.
Urodynamics: Mirabegron at doses of 50 mg and 100 mg once daily for 12 weeks in men with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) showed no effect on cystometry parameters and was safe and well tolerated. The effects of mirabegron on maximum flow rate and detrusor pressure at maximum flow rate were assessed in this urodynamic study consisting of 200 male patients with LUTS and BOO. Administration of mirabegron at doses of 50 mg and 100 mg once daily for 12 weeks did not adversely affect the maximum flow rate or detrusor pressure at maximum flow rate. In this study in male patients with LUTS/BOO, the adjusted mean (SE) change from baseline to end of treatment in post void residual volume (mL) was 0.55 (10.702), 17.89 (10.19), 30.77 (10.598) for the placebo, mirabegron 50 mg and 100 mg treatment groups.
Effect on QT Interval: Mirabegron at doses of 50 or 100 mg had no effect on the QT interval individually corrected for heart rate (QTcI interval) when evaluated either by sex or by the overall group.
A thorough QT (TQT) study (n=164 healthy male and n=153 healthy female volunteers with a mean age of 33 years) evaluated the effect of repeat oral dosing of mirabegron at the indicated dose (50 mg once daily) and 2 supra-therapeutic doses (100 mg and 200 mg once daily) on the QTcI interval. The supra-therapeutic doses represent approximately 2.6- and 6.5-fold the exposure of the therapeutic dose, respectively. A single 400-mg dose of moxifloxacin was used as a positive control. Each dose level of mirabegron and moxifloxacin was evaluated in separate treatment arms each including placebo-control (parallel cross-over design). For both males and females administered mirabegron at 50 mg and 100 mg, the upper bound of the 1-sided 95% confidence interval did not exceed 10 msec at any time point for the largest time-matched mean difference from placebo in the QTcI interval. In females administered mirabegron at the 50 mg dose, the mean difference from placebo on QTcI interval at 5 hrs post-dose was 3.67 msec (upper bound of the 1-sided 95% CI 5.72 msec). In males, the difference was 2.89 msec (upper bound of the 1-sided 95% CI 4.9 msec). At a mirabegron dose of 200 mg, the QTcI interval did not exceed 10 msec at any time point in males, while in females the upper bound of the 1-sided 95% confidence interval did exceed 10 msec between 0.5–6 hrs, with a maximum difference from placebo at 5 hrs where the mean effect was 10.42 msec (upper bound of the 1-sided 95% CI 13.44 msec). Results for QTcF and QTcIf were consistent with QTcI.
In this TQT study, mirabegron increased heart rate on ECG in a dose-dependent manner across the 50-200 mg dose range examined. The maximum mean difference from placebo in heart rate ranged from 6.7 beats per minute (bpm) with mirabegron 50 mg up to 17.3 bpm with mirabegron 200 mg in healthy subjects.
Effects on Pulse Rate and Blood Pressure in Patient with OAB: In OAB patients (mean age of 59 years) across three 12-week phase 3 double-blind, placebo-controlled studies receiving mirabegron 50 mg once daily, an increase in mean difference from placebo of approximately 1 bpm for pulse rate and approximately ≤1 mmHg in systolic blood pressure/diastolic blood pressure (SBP/DBP) was observed. Changes in pulse rate and blood pressure are reversible upon discontinuation of treatment.
Effect on Intraocular Pressure (IOP): Mirabegron 100 mg once daily did not increase IOP in healthy subjects after 56 days of treatment. In a phase 1 study assessing the effect of mirabegron on IOP using Goldmann applanation tonometry in 310 healthy subjects, a dose of mirabegron 100 mg was non-inferior to placebo for the primary endpoint of the treatment difference in mean change from baseline to day 56 in subject-average IOP; the upper bound of the 2-sided 95% CI of the treatment difference between mirabegron 100 mg and placebo was 0.3 mmHg.
Clinical Efficacy and Safety:
Efficacy of mirabegron was evaluated in 3 phase 3 randomized, double-blind, placebo-controlled, 12-week studies for the treatment of overactive bladder with symptoms of urgency and frequency with or without incontinence. Female (72%) and male (28%) patients with a mean age of 59 years (range 18-95 years) were included. The study population consisted of approximately 48% antimuscarinic treatment naive patients as well as approximately 52% patients previously treated with antimuscarinic medication. In 1 study, 495 patients received an active control (tolterodine prolonged-release formulation).
The co-primary efficacy endpoints were change from baseline to end of treatment in mean number of incontinence episodes per 24 hrs and change from baseline to end of treatment in mean number of micturitions per 24 hrs based on a 3-day micturition diary. Mirabegron demonstrated statistically significant larger improvements compared to placebo for both co-primary endpoints as well as secondary endpoints (see Tables 1 and 2).
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Mirabegron 50 mg once daily was effective at the first measured time point of week 4, and efficacy was maintained throughout the 12-week treatment period. A randomized, active-controlled, long-term study demonstrated that efficacy was maintained throughout a 1-year treatment period.
Subjective Improvement in Health-Related Quality of Life Measurements:
In the three 12-week phase 3 double blind, placebo controlled studies, treatment of the symptoms of OAB with mirabegron once daily resulted in a statistically significant improvement over placebo on the following health-related quality of life measures: Treatment satisfaction and symptom bother.
Efficacy in Patients With or Without Prior OAB Antimuscarinic Therapy:
Efficacy was demonstrated in patients with and without prior OAB antimuscarinic therapy. In addition, mirabegron showed efficacy in patients who previously discontinued OAB antimuscarinic therapy due to insufficient effect (see Table 3).
Click on icon to see table/diagram/image
The European Medicines Agency has deferred the obligation to submit the results of studies with Betmiga in ≥1 subsets of the paediatric population in “Treatment of idiopathic overactive bladder” and “Treatment of neurogenic detrusor overactivity” (see Dosage & Administration for information on paediatric use).
After oral administration of mirabegron in healthy volunteers, mirabegron is absorbed to reach peak plasma concentrations (Cmax
) between 3 hrs and 4 hrs. The absolute bioavailability increased from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax
and AUC increased more than dose proportionally over the dose range. In the overall population of males and females, a 2-fold increase in dose from mirabegron 50-100 mg increased Cmax
by approximately 2.9- and 2.6‑fold, respectively, whereas a 4-fold increase in dose from mirabegron 50-200 mg increased Cmax
by approximately 8.4- and 6.5-fold. Steady-state concentrations are achieved within 7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure of mirabegron at steady state is approximately double that seen after a single dose.
Effect of Food on Absorption:
Co-administration of a 50-mg tablet with a high-fat meal reduced mirabegron Cmax
and AUC by 45% and 17%, respectively. A low-fat meal decreased mirabegron Cmax
and AUC by 75% and 51%, respectively. In the phase 3 studies, mirabegron was administered with or without food and demonstrated both safety and efficacy. Therefore, mirabegron can be taken with or without food at the recommended dose.
Mirabegron is extensively distributed. The volume of distribution at steady state (Vss
) is approximately 1,670 L. Mirabegron is bound (approximately 71%) to human plasma proteins, and shows moderate affinity for albumin and α-1 acid glycoprotein. Mirabegron distributes to erythrocytes. In vitro
erythrocyte concentrations of 14
C-mirabegron were about 2-fold higher than in plasma.
Mirabegron is metabolized via multiple pathways involving dealkylation, oxidation, (direct) glucuronidation and amide hydrolysis. Mirabegron is the major circulating component following a single dose of 14
C-mirabegron. Two major metabolites were observed in human plasma; both are phase 2 glucuronides representing 16% and 11% of total exposure. These metabolites are not pharmacologically active.
Based on in vitro
studies, mirabegron is unlikely to inhibit the metabolism of co-administered medicinal products metabolized by the following cytochrome P-450 enzymes: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP2E1 because mirabegron did not inhibit the activity of these enzymes at clinically relevant concentrations. Mirabegron did not induce CYP1A2 or CYP3A. Mirabegron is predicted not to cause clinically relevant inhibition of OCT-mediated drug transport.
Although in vitro
studies suggest a role for CYP2D6 and CYP3A4 in the oxidative metabolism of mirabegron, in vivo
results indicate that these isozymes play a limited role in the overall elimination. In vitro
and ex vivo
studies have shown the involvement from butyrylcholinesterase, UGT and possibly alcohol dehydrogenase (ADH) in the metabolism of mirabegron, in addition to CYP3A4 and CYP2D6.
In healthy subjects who are genotypically poor metabolisers of CYP2D6 substrates (used as a surrogate for CYP2D6 inhibition), mean Cmax
of a single 160-mg dose of a mirabegron IR formulation were 14% and 19% higher than in extensive metabolisers, indicating that CYP2D6 genetic polymorphism has minimal impact on the mean plasma exposure to mirabegron. Interaction of mirabegron with a known CYP2D6 inhibitor is not expected and was not studied. No dose adjustment is needed for mirabegron when administered with CYP2D6 inhibitors or in patients who are CYP2D6 poor metabolisers.
Total body clearance (CLtot
) from plasma is approximately 57 L/hr. The terminal elimination half-life (t½
) is approximately 50 hrs. Renal clearance (CLR
) is approximately 13 L/hr, which corresponds to nearly 25% of CLtot
. Renal elimination of mirabegron is primarily through active tubular secretion along with glomerular filtration. The urinary excretion of unchanged mirabegron is dose-dependent and ranges from approximately 6% after a daily dose of 25 mg to 12.2% after a daily dose of 100 mg. Following the administration of 14
C-mirabegron 160 mg to healthy volunteers, approximately 55% of the radiolabel was recovered in the urine and 34% in the faeces. Unchanged mirabegron accounted for 45% of the urinary radioactivity, indicating the presence of metabolites. Unchanged mirabegron accounted for the majority of the faecal radioactivity.
and AUC of mirabegron and its metabolites following multiple oral doses in elderly volunteers (≥65 years) were similar to those in younger volunteers (18-45 years).
and AUC are approximately 40-50% higher in females than in males. Gender differences in Cmax
and AUC are attributed to differences in body weight and bioavailability.
The pharmacokinetics of mirabegron are not influenced by race.
Following single dose administration of mirabegron 100 mg in volunteers with mild renal impairment (eGFR-MDRD 60-89 mL/min/1.73 m2
), mean mirabegron Cmax
and AUC were increased by 6% and 31% relative to volunteers with normal renal function. In volunteers with moderate renal impairment (eGFR-MDRD 30-59 mL/min/1.73 m2
and AUC were increased by 23% and 66%, respectively. In volunteers with severe renal impairment (eGFR-MDRD 15-29 mL/min/1.73 m2
), mean Cmax
and AUC values were 92% and 118% higher. Mirabegron has not been studied in patients with end stage renal disease (GFR <15 mL/min/1.73 m2
or patients requiring haemodialysis).
Following single dose administration of mirabegron 100 mg in volunteers with mild hepatic impairment (Child-Pugh class A), mean mirabegron Cmax
and AUC were increased by 9% and 19% relative to volunteers with normal hepatic function. In volunteers with moderate hepatic impairment (Child-Pugh class B), mean Cmax
and AUC values were 175% and 65% higher. Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh class C).
Toxicology: Preclinical Safety Data:
Preclinical studies have identified target organs of toxicity that are consistent with clinical observations. Transient increases in liver enzymes and hepatocyte changes (necrosis and decrease in glycogen particles) were seen in rats. An increase in heart rate was observed in rats, rabbits, dogs and monkeys. Genotoxicity and carcinogenicity studies have shown no genotoxic or carcinogenic potential in vivo
No effects on fertility were seen at sub-lethal doses [human equivalent dose was 19-fold higher than the maximum human recommended dose (MHRD)]. The main findings in rabbit embryofetal development studies included malformations of the heart (dilated aorta, cardiomegaly) at systemic exposures 36‑fold higher than observed at the MHRD. In addition, malformations of the lung (absent accessory lobe of the lung) and increased post-implantation loss were observed in the rabbit at systemic exposures 14‑fold higher than observed at the MHRD, while in the rat reversible effects on ossification were noted (wavy ribs, delayed ossification, decreased number of ossified sternebrae, metacarpi or metatarsi) at systemic exposures 22-fold higher than observed at the MHRD. The observed embryofetal toxicity occurred at doses associated with maternal toxicity.The cardiovascular malformations observed in the rabbit were shown to be mediated via activation of the β1
Pharmacokinetic studies performed with radiolabelled mirabegron have shown that the parent compound and/or its metabolites are excreted in the milk of rats at levels that were approximately 1.7‑fold higher than plasma levels at 4 hrs post-administration (see Use in pregnancy & lactation under Precautions).